November 13, 2013

Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, ranked number 290 on Deloitte’s Technology Fast 500, a ranking of the 500 fastest growing technology, life sciences, telecommunications and media companies in North America.

The company qualified for the recognition as a biotech/pharma company using its proprietary intellectual property in developing FDA approved veterinary generics to drive revenue growth of 304 percent.

“Putney has invested millions of dollars in R&D to develop FDA approved generics of expensive branded veterinary drugs,” Jean Hoffman, president and CEO, said. “We are the only companion animal health company that is focused entirely on developing and commercializing veterinary generics, to help make pet healthcare more affordable.”

Share This Story On:

Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Dog & Cat Needs

With dogs and cats being members of the family, there's vital information to know in order to serve their pet parents.

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Enews Subscribe

Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up